# Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

> **NCT03766763** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **French Innovative Leukemia Organisation** · enrollment: 82 (estimated)

## Conditions studied

- Chronic Lymphoid Leukemia

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03766763
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-22
- **Primary completion:** 2022-01-01
- **Final completion:** 2030-04-24
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03766763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03766763, "Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03766763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*